South Korea · Delayed Price · Currency is KRW Y-Biologics Statistics
Total Valuation
Y-Biologics has a market cap or net worth of KRW 139.07 billion. The enterprise value is 117.05 billion.
| Market Cap | 139.07B |
| Enterprise Value | 117.05B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Y-Biologics has 15.37 million shares outstanding. The number of shares has increased by 2.34% in one year.
| Current Share Class | 15.37M |
| Shares Outstanding | 15.37M |
| Shares Change (YoY) | +2.34% |
| Shares Change (QoQ) | +1.11% |
| Owned by Insiders (%) | 29.48% |
| Owned by Institutions (%) | 3.28% |
| Float | 10.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.87 |
| PB Ratio | 8.09 |
| P/TBV Ratio | 8.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.81, with a Debt / Equity ratio of 0.96.
| Current Ratio | 23.81 |
| Quick Ratio | 23.17 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.52 |
| Interest Coverage | -4.41 |
Financial Efficiency
Return on equity (ROE) is -297.87% and return on invested capital (ROIC) is -32.50%.
| Return on Equity (ROE) | -297.87% |
| Return on Assets (ROA) | -23.92% |
| Return on Invested Capital (ROIC) | -32.50% |
| Return on Capital Employed (ROCE) | -27.17% |
| Weighted Average Cost of Capital (WACC) | 6.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.70% in the last 52 weeks. The beta is 0.22, so Y-Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -32.70% |
| 50-Day Moving Average | 9,764.00 |
| 200-Day Moving Average | 19,944.80 |
| Relative Strength Index (RSI) | 45.98 |
| Average Volume (20 Days) | 43,442 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Y-Biologics had revenue of KRW 3.17 billion and -49.95 billion in losses. Loss per share was -3,303.05.
| Revenue | 3.17B |
| Gross Profit | 2.56B |
| Operating Income | -13.18B |
| Pretax Income | -49.95B |
| Net Income | -49.95B |
| EBITDA | -11.26B |
| EBIT | -13.18B |
| Loss Per Share | -3,303.05 |
Balance Sheet
The company has 38.49 billion in cash and 16.47 billion in debt, with a net cash position of 22.02 billion or 1,432.99 per share.
| Cash & Cash Equivalents | 38.49B |
| Total Debt | 16.47B |
| Net Cash | 22.02B |
| Net Cash Per Share | 1,432.99 |
| Equity (Book Value) | 17.20B |
| Book Value Per Share | 1,120.67 |
| Working Capital | 38.03B |
Cash Flow
In the last 12 months, operating cash flow was -9.06 billion and capital expenditures -1.77 billion, giving a free cash flow of -10.82 billion.
| Operating Cash Flow | -9.06B |
| Capital Expenditures | -1.77B |
| Depreciation & Amortization | 1.92B |
| Net Borrowing | 34.31B |
| Free Cash Flow | -10.82B |
| FCF Per Share | -704.31 |
Margins
| Gross Margin | 80.68% |
| Operating Margin | -415.87% |
| Pretax Margin | -1,575.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Y-Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.34% |
| Shareholder Yield | -2.34% |
| Earnings Yield | -35.92% |
| FCF Yield | -7.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Y-Biologics has an Altman Z-Score of 0.69 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.69 |
| Piotroski F-Score | 3 |